FDA Brief

Warning letters Drugs

FDA warning letter to

Lexia LLC

High riskIssued Apr 7Posted Apr 28Center for Drug Evaluation and Research (CDER)

FDA cited Lexia for manufacturing violations in an OTC topical pain relief drug, including missing release and component testing.

What happened

FDA inspected Lexia’s drug manufacturing facility from September 23 to 29, 2025 and found significant violations of current good manufacturing practice (CGMP), the rules for drug manufacturing. FDA found inadequate finished-product release testing (only viscosity, pH, and color were tested, not active ingredient identity/strength or objectionable microorganisms), no component identity testing or supplier qualification, no stability data for the labelled expiry, no process validation, and an inadequate quality unit. Lexia said it would stop making drug products and deregistered its drug facility.

What FDA found

  1. Lexia did not adequately test each finished batch before release for active ingredient identity and strength or for objectionable microorganisms; it tested only viscosity, pH, and color.

    21 CFR 211.165(a) and 211.165(b)
  2. Lexia did not test incoming components for identity and did not establish that suppliers’ certificate-of-analysis results were reliable.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  3. Lexia assigned an expiry period to its OTC topical pain relief product without stability testing to support it.

    21 CFR 211.137(a)
  4. Lexia lacked process validation data showing its manufacturing process could reproducibly make uniform, quality drug product.

    21 CFR 211.100(a)
  5. Lexia lacked an adequate quality unit and written quality procedures for investigations, reserve samples, complaints, recalls, batch records, cleaning, and training.

    21 CFR 211.22(a) and (d); 21 CFR 211.192; 21 CFR 211.180(e); 21 CFR 211.170(b); 21 CFR 211.198(a); 21 CFR 211.150(b); 21 CFR 211.188(b); 21 CFR 211.67(b); 21 CFR 211.25(a)

What FDA wants

FDA asks Lexia to respond in writing within 15 working days with the actions it has taken to correct the violations and prevent recurrence. If Lexia resumes drug manufacturing, FDA says it must notify the office first and provide a summary of its corrective and preventive actions.

Who should pay attention

  • brands that buy OTC topical drugs from contract manufacturers
  • companies that rely on supplier certificates of analysis
  • quality teams responsible for stability and process validation

This is a summary. Read the original letter on fda.gov.

Lexia LLC's FDA history

Recalls in the last 12 months

Sep 9 Class II Lexia LLC
Drug
Broadway Joe's Pain Cream, (Histamine Dihydrochloride 0.025%), 1500mg CBD Isolate, 1000mg Hempseed oil, 2 oz-jar, Produced for Broadway Joe's, Franklin, TN, 37067, NDC 83088-8120-5, UPC 8 50041 64003 7
CGMP Deviations: Potential contamination of raw material
Sep 9 Class II Lexia LLC
Drug
Broadway Joe's Pain Cream, 3000 gm CBD, (Histamine Dihydrochloride 0.025%) (CDB Isolate 3000mg, HempSeed Oil 2000mg),4 oz-jar, Produced for Broadway Joe's, Franklin, TN, 37067, NDC 83088-8120-6; UPC 8 50041 64004 4
CGMP Deviations: Potential contamination of raw material

Full company page

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk